MNOV – Medicinova Inc
Float Short %
0.6
Margin Of Safety %
Put/Call OI Ratio
0.16
EPS Next Q Diff
-0.01
EPS Last/This Y
-0.27
EPS This/Next Y
0.18
Price
1.87
Target Price
10
Analyst Recom
1
Performance Q
52.46
Relative Volume
0.27
Beta
0.54
Ticker: MNOV
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | MNOV | 1.26 | 0.04 | 999.99 | 496 |
| 2025-12-29 | MNOV | 1.29 | 0.04 | 999.99 | 496 |
| 2025-12-30 | MNOV | 1.285 | 0.04 | 999.99 | 496 |
| 2025-12-31 | MNOV | 1.29 | 0.04 | 999.99 | 496 |
| 2026-01-02 | MNOV | 1.32 | 0.04 | 999.99 | 496 |
| 2026-01-05 | MNOV | 1.38 | 0.04 | 0.00 | 500 |
| 2026-01-06 | MNOV | 1.395 | 0.04 | 0.00 | 500 |
| 2026-01-07 | MNOV | 1.409 | 0.04 | 0.00 | 500 |
| 2026-01-08 | MNOV | 1.43 | 0.04 | 0.00 | 500 |
| 2026-01-09 | MNOV | 1.52 | 0.04 | 0.00 | 500 |
| 2026-01-12 | MNOV | 1.45 | 0.04 | 0.00 | 500 |
| 2026-01-13 | MNOV | 1.45 | N/A | N/A | 0 |
| 2026-01-14 | MNOV | 1.4436 | N/A | N/A | 0 |
| 2026-01-15 | MNOV | 1.5942 | N/A | N/A | 0 |
| 2026-01-16 | MNOV | 1.6 | N/A | N/A | 0 |
| 2026-01-20 | MNOV | 1.69 | 0.45 | 0.00 | 48 |
| 2026-01-21 | MNOV | 1.685 | 0.36 | 0.00 | 57 |
| 2026-01-22 | MNOV | 1.67 | 0.36 | 0.00 | 57 |
| 2026-01-23 | MNOV | 1.87 | 0.16 | 0.00 | 108 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | MNOV | 1.27 | -100.0 | - | -0.50 |
| 2025-12-29 | MNOV | 1.29 | -100.0 | - | -0.50 |
| 2025-12-30 | MNOV | 1.29 | -100.0 | - | -0.50 |
| 2025-12-31 | MNOV | 1.30 | -100.0 | - | -0.50 |
| 2026-01-02 | MNOV | 1.32 | -100.0 | - | -0.50 |
| 2026-01-05 | MNOV | 1.39 | -100.0 | - | -0.50 |
| 2026-01-06 | MNOV | 1.39 | -100.0 | - | -0.50 |
| 2026-01-07 | MNOV | 1.40 | -100.0 | - | -0.50 |
| 2026-01-08 | MNOV | 1.43 | -100.0 | - | -0.50 |
| 2026-01-09 | MNOV | 1.52 | -58.3 | - | -0.50 |
| 2026-01-12 | MNOV | 1.45 | -58.3 | - | -0.50 |
| 2026-01-13 | MNOV | 1.47 | -58.3 | - | -0.50 |
| 2026-01-14 | MNOV | 1.45 | -58.3 | - | -0.50 |
| 2026-01-15 | MNOV | 1.58 | -58.3 | - | -0.50 |
| 2026-01-16 | MNOV | 1.61 | -58.3 | - | -0.50 |
| 2026-01-20 | MNOV | 1.69 | -58.3 | - | -0.50 |
| 2026-01-21 | MNOV | 1.68 | -58.3 | - | -0.50 |
| 2026-01-22 | MNOV | 1.66 | -58.3 | - | -0.50 |
| 2026-01-23 | MNOV | 1.87 | -58.3 | - | -0.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | MNOV | 0.00 | -0.11 | 0.61 |
| 2025-12-29 | MNOV | 0.00 | -0.11 | 0.61 |
| 2025-12-30 | MNOV | 0.00 | -0.11 | 0.61 |
| 2025-12-31 | MNOV | 0.00 | -0.11 | 0.61 |
| 2026-01-02 | MNOV | 0.00 | -0.11 | 0.61 |
| 2026-01-05 | MNOV | 0.00 | -0.11 | 0.61 |
| 2026-01-06 | MNOV | 0.00 | -0.11 | 0.61 |
| 2026-01-07 | MNOV | 0.00 | -0.11 | 0.61 |
| 2026-01-08 | MNOV | 0.00 | -0.11 | 0.61 |
| 2026-01-09 | MNOV | 0.00 | -0.11 | 0.61 |
| 2026-01-12 | MNOV | 0.00 | -0.11 | 0.61 |
| 2026-01-13 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-14 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-15 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-16 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-20 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-21 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-22 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-23 | MNOV | 0.00 | -0.11 | 0.60 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.06
Avg. EPS Est. Current Quarter
-0.12
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
Institutional Transactions
-0.11
Beta
0.54
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
22
Growth Score
18
Sentiment Score
71
Actual DrawDown %
82.8
Max Drawdown 5-Year %
-87.1
Target Price
10
P/E
Forward P/E
PEG
P/S
351.6
P/B
2.07
P/Free Cash Flow
EPS
-0.24
Average EPS Est. Cur. Y
-0.5
EPS Next Y. (Est.)
-0.32
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-4656.65
Relative Volume
0.27
Return on Equity vs Sector %
-54.6
Return on Equity vs Industry %
-38.6
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
MediciNova, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 13
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
stock quote shares MNOV – Medicinova Inc Stock Price stock today
news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MNOV – Medicinova Inc yahoo finance google finance
stock history MNOV – Medicinova Inc invest stock market
stock prices MNOV premarket after hours
ticker MNOV fair value insiders trading